Indivior Pharmaceuticals (INDV) Accumulated Expenses (2023 - 2026)

Indivior Pharmaceuticals has reported Accumulated Expenses for 4 years, with the latest figure at $14.0 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses fell 86.67% year-over-year to $14.0 million in Q2 2026; TTM through Jun 2026 was $14.0 million, a 86.67% decrease from a year earlier, with the FY2025 full-year figure at $42.0 million, down 57.58% from the prior year.
• Accumulated Expenses was $14.0 million for Q2 2026 at Indivior Pharmaceuticals, roughly flat from $14.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $492.0 million in Q4 2023, with the low at $14.0 million in Q1 2026.
• Average Accumulated Expenses over 4 years is $122.1 million, with a median of $102.0 million recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses tumbled 57.58% in 2025, then plunged 86.67% in 2026.
• Over 4 years, Accumulated Expenses stood at $492.0 million in 2023, then slumped by 79.88% to $99.0 million in 2024, then sank by 57.58% to $42.0 million in 2025, then slumped by 66.67% to $14.0 million in 2026.
• The last three Accumulated Expenses figures came in at $14.0 million (Q2 2026), $14.0 million (Q1 2026), and $42.0 million (Q4 2025), per Business Quant data.